Company intelligence / Profile preview

Dongbao Zixing (Hangzhou) Biomedical Co., Ltd.

Hangzhou, Zhejiang Sheng, Chinathdb.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Dongbao Zixing is advancing novel small molecule and peptide therapeutics targeting metabolic and endocrine disorders. Its lead assets include dual and triple receptor agonists/inhibitors for obesity, gout, and type 2 diabetes. The most advanced programs have reached Phase 2 clinical trials as of early 2025. Clinical results have not been publicly detailed yet.

Therapeutic areas: Metabolic DisordersEndocrinologyRheumatology
Modalities: Small molecule drugsSynthetic peptides
Industry: Biotech

Drug pipeline

3 assets

THDBH110

Unknown

2 more assets in the full pipeline.

Request access →

Partnerships

WuXi AppTec

Beyond the preview

Go deeper on Dongbao Zixing (Hangzhou) Biomedical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dongbao Zixing (Hangzhou) Biomedical Co., Ltd..

Explore the full profile